Back to Results

Biosyent Inc (BIOYF)

BioSyent Inc. is a Canada-based healthcare company focused on acquiring, licensing, developing, and marketing pharmaceutical and other healthcare products in Canada and international markets. The company’s portfolio includes products used in areas such as iron deficiency anemia, hormone replacement therapy, polycystic ovarian syndrome symptoms, vaginal dryness and mucosal healing, oral mucositis pain relief, catheterization support, and rectal healing. Key products cited include FeraMAX Pd Therapeutic 150, FeraMAX Pd Maintenance 45, FeraMAX Pd Powder 15, Tibella, Inofolic, RepaGyn, Gelclair, Cathejell, and Proktis-M. BioSyent distributes its products through wholesalers and retail pharmacy chains. Incorporated in 2006 and formerly known as Hedley Technologies Inc., the company is headquartered in Mississauga, Canada. The listed security is common stock on OTC Markets.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Overall Financial Health Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
OTC-BIOY.F
$12.08
-0.1% Downside
Fair
Not available
Not available
Great
1.3%
November 12, 2026
19.4x
4.2x
3.4x
136.9 M
128.7 M
1.6%
80.8%
15.4
24.0%
116.1%
Valuation • Fair Value

Biosyent Inc (OTC-BIOY.F) Fair Value by Valuation Model

Review the available estimates for Biosyent Inc (OTC-BIOY.F), including DCF Fair Value, Ben Graham Formula Value, DDM Fair Value, EPV Fair Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$12.08

Estimated downside of 0.1% versus the current market price.

Fair Value Confidence

High

Confidence level for the primary fair value estimate.

DCF Fair Value

$12.48

Discounted cash flow valuation reference.

Ben Graham Formula Value

$6.92

Classic Ben Graham valuation formula reference.

DDM Fair Value

$19.01

Dividend discount model valuation reference.

EPV Fair Value

$10.78

Earnings power value estimate.

Comps Fair Value

$9.59

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use the 7 available valuation references for Biosyent Inc (OTC-BIOY.F) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Biosyent Inc (OTC-BIOY.F)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

39.255 M

Current operating scale indicator.

Revenue Forecast

52.26 M

Forward revenue estimate.

EBITDA

10.494 M

Current operating profitability reference.

EBITDA Forecast

12.637 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Biosyent Inc (OTC-BIOY.F) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Biosyent Inc (OTC-BIOY.F)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Great

Positive financial-health read.

Piotroski Score

4

Mid-range quality score.

Beneish M-Score

-2.34

No elevated caution signal from this screen.

Altman Z-Score

15.4

Relatively strong balance-sheet zone.

FCF / Net Income

116.1%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Biosyent Inc (OTC-BIOY.F). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Biosyent Inc (OTC-BIOY.F)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 12, 2026

Days to Earnings

19

Dividend Yield

1.3%

Current income yield reference.

Payout Ratio

24.0%

Dividend payout reference.

How to read events and dividends

This section helps investors track time-sensitive items for Biosyent Inc (OTC-BIOY.F), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Technical Outlook

Technical Signals by Time Frame

Review the technical signals currently available for this stock across supported time frames.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for Biosyent Inc (OTC-BIOY.F) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Buy

The 1-hour technical read for Biosyent Inc (OTC-BIOY.F) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Buy

The daily technical read for Biosyent Inc (OTC-BIOY.F) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Buy

The weekly technical read for Biosyent Inc (OTC-BIOY.F) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Buy

The monthly technical read for Biosyent Inc (OTC-BIOY.F) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

FAQ • Fast Investor Answers

Biosyent Inc (OTC-BIOY.F) Stock FAQ

Data-supported answers about Biosyent Inc (OTC-BIOY.F), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$12.08
Estimated downside 0.1%
Valuation Rating
Near Fair Value
Price is close to fair value
Financial Health
Great
Current financial-health read

The current fair value estimate for Biosyent Inc (OTC-BIOY.F) is $12.08. This implies an estimated downside of 0.1% versus the current market price.

Based on the current fair value estimate, the stock is trading close to its estimated fair value.

The current financial health read for Biosyent Inc (OTC-BIOY.F) is Great. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Biosyent Inc (OTC-BIOY.F) is November 12, 2026.

Based on the current data, dividend yield is 1.3%.

The current P/E ratio listed for Biosyent Inc (OTC-BIOY.F) is 19.4x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Biosyent Inc is 136.9 M.

The current enterprise value listed for Biosyent Inc is 128.7 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Biosyent Inc is OTC-BIOY.F, and the stock is listed on OTC Markets.

Biosyent Inc (OTC-BIOY.F) is listed on OTC Markets.

The current debt-to-total-capital ratio listed for Biosyent Inc is 1.6%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Biosyent Inc is 80.8%. Free float helps investors understand how much of the share base is available for public trading.

Similar Pharmaceuticals Stocks View more on OTC Markets

Comparable companies from the same industry, limited to one security per issuer.

LLY NYSE Eli Lilly and Company Fair Value Fair Market Cap 1,135.1 B
JNJ NYSE Johnson & Johnson Fair Value Fair Market Cap 635.8 B
MRK NYSE Merck & Company Inc Fair Value Fair Market Cap 358.4 B
NVS NYSE Novartis AG ADR Fair Value Fair Market Cap 294.8 B
NVO NYSE Novo Nordisk A/S Fair Value Bargain Market Cap 172.3 B
PFE NYSE Pfizer Inc Fair Value Fair Market Cap 171.2 B
BMY NYSE Bristol-Myers Squibb Company Fair Value Fair Market Cap 125.6 B
GSK NYSE GSK plc DRC Fair Value Undervalued Market Cap 101.5 B
SNY NASDAQ Sanofi ADR Fair Value Bargain Market Cap 99.408 B
TAK NYSE Takeda Pharmaceutical Co Ltd ADR Fair Value Fair Market Cap 65.044 B
TEVA NYSE Teva Pharma Industries Ltd ADR Fair Value Fair Market Cap 45.924 B
HLN NYSE HALEON PLC ADR Fair Value Fair Market Cap 44.905 B
RPRX NASDAQ Royalty Pharma Plc Fair Value Fair Market Cap 36.72 B
ZTS NYSE Zoetis Inc Fair Value Undervalued Market Cap 33.484 B
VTRS NASDAQ Viatris Inc Fair Value Fair Market Cap 20.675 B
JAZZ NASDAQ Jazz Pharmaceuticals PLC Fair Value Fair Market Cap 13.892 B
ELAN NYSE Elanco Animal Health Fair Value Fair Market Cap 11.251 B
RDY NYSE Dr. Reddy’s Laboratories Ltd ADR Fair Value Fair Market Cap 10.74 B
CORT NASDAQ Corcept Therapeutics Incorporated Fair Value Fair Market Cap 9.281 B
AXSM NASDAQ Axsome Therapeutics Inc Fair Value Undervalued Market Cap 7.597 B